Latest News

Senhwa Biosciences Silmitasertib of Basal Cell Carcinoma Trial Completed 1st Patient Enrollment

Apr

17

2019

Senhwa Biosciences Silmitasertib filed IND of Basal Cell Carcinoma approved by FDA

Nov

01

2018

PBTC and Senhwa sign cooperation agreement to develop CX-4945 for pediatric brain tumor treatment

Jun

12

2018

Senhwa announces the result of phase I data of CX-5461 in the treatment of Hematological malignancies

Dec

12

2017

Senhwa won the National Innovation Award with novelty of CX-5461

Nov

17

2017

Senhwa CX-5461 phase I data of Hematological malignancies was accepted and will be published at the 59th ASH annual meeting

Oct

16

2017

Senhwa CX-5461 in line with the trend of DDR mechanism in anticancer drug development

Sep

19

2017

Notice of US subsidiary changes corporate name

Sep

07

2017